- Home
- FGNX vs RANI Comparison
FGNX vs RANI Comparison
Compare FGNX & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGNX
- RANI
- Stock Information
- Founded
- FGNX 1932
- RANI 2012
- Country
- FGNX United States
- RANI United States
- Employees
- FGNX N/A
- RANI N/A
- Industry
- FGNX Property-Casualty Insurers
- RANI Medicinal Chemicals and Botanical Products
- Sector
- FGNX Finance
- RANI Health Care
- Exchange
- FGNX Nasdaq
- RANI Nasdaq
- Market Cap
- FGNX 25.2M
- RANI 23.2M
- IPO Year
- FGNX N/A
- RANI 2021
- Fundamental
- Price
- FGNX $10.27
- RANI $0.46
- Analyst Decision
- FGNX
- RANI Strong Buy
- Analyst Count
- FGNX 0
- RANI 4
- Target Price
- FGNX N/A
- RANI $7.75
- AVG Volume (30 Days)
- FGNX 180.5K
- RANI 693.1K
- Earning Date
- FGNX 08-07-2025
- RANI 08-07-2025
- Dividend Yield
- FGNX N/A
- RANI N/A
- EPS Growth
- FGNX N/A
- RANI N/A
- EPS
- FGNX 2.41
- RANI N/A
- Revenue
- FGNX $24,184,000.00
- RANI $1,200,000.00
- Revenue This Year
- FGNX N/A
- RANI N/A
- Revenue Next Year
- FGNX N/A
- RANI N/A
- P/E Ratio
- FGNX $5.08
- RANI N/A
- Revenue Growth
- FGNX 24.03
- RANI N/A
- 52 Week Low
- FGNX $10.10
- RANI $0.39
- 52 Week High
- FGNX $41.25
- RANI $3.75
- Technical
- Relative Strength Index (RSI)
- FGNX N/A
- RANI 38.27
- Support Level
- FGNX N/A
- RANI $0.45
- Resistance Level
- FGNX N/A
- RANI $0.58
- Average True Range (ATR)
- FGNX 0.00
- RANI 0.04
- MACD
- FGNX 0.00
- RANI -0.01
- Stochastic Oscillator
- FGNX 0.00
- RANI 10.34
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.